Understand the source comparison
Best Peptides for Fibromyalgia Treatment: Mechanism Comparison
BPC-157 NF-kB inhibition, VEGF upregulation, nitric oxide stabilisation Chronic widespread pain, inflammation, tissue hypoxia 200–500 mcg/day subcutaneous Preclinical models + case series Strongest anti-inflammatory profile. Addresses cytokine-driven pain dire
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- NF-kB inhibition, VEGF upregulation, nitric oxide stabilisation
- Chronic widespread pain, inflammation, tissue hypoxia
- 200–500 mcg/day subcutaneous
- Preclinical models + case series
- Strongest anti-inflammatory profile. Addresses cytokine-driven pain directly
- Thymosin Beta-4
- VEGF promotion, TGF-beta suppression, actin-binding tissue repair
- Fatigue, muscle dysfunction, impaired tissue recovery
- 2–5 mg twice weekly subcutaneous
- Preclinical models + musculoskeletal injury trials
- Best for metabolic and tissue-level dysfunction. Slower onset but sustained repair
- Cerebrolysin
- BDNF/NGF delivery, synaptic plasticity restoration, pain pathway normalisation
- Cognitive fog, central sensitization, neuropathic pain
- 5–10 mL 5×/week IV or IM for 4 weeks
- Double-blind RCTs in chronic pain populations
- Only peptide with controlled human trial data in pain. Targets CNS mechanisms
- KPV (Lysine-Proline-Valine)
- Alpha-MSH mimetic, anti-inflammatory, gut-brain axis modulation
- GI symptoms, systemic inflammation
- 500 mcg–1 mg/day subcutaneous
- Preclinical inflammatory bowel models
- Promising for patients with overlapping IBS. Limited fibromyalgia-specific data
- Dihexa
- BDNF amplification, HGF/c-Met pathway activation
- Memory impairment, executive dysfunction
- 1–5 mg/day oral or subcutaneous
- Cognitive enhancement models
- Cognitive benefits documented but pain pathway evidence is indirect
- The comparison reveals something critical: no peptide treats 'fibromyalgia' as a single entity. BPC-157 targets inflammation. Thymosin beta-4 targets tissue repair. Cerebrolysin targets the central nervous system. Effective protocols often combine two compounds addressing different pathways rather than relying on one peptide to correct all dysfunction.